We explored the effects of vitamin D3 levels on children suffering from eczema in a study involving 159 pediatric patients. The children were grouped based on the severity of their eczema, allowing us to see how varying levels of vitamin A, vitamin D3, and certain inflammatory markers changed with the severity of the condition.
Our findings revealed that as the severity of eczema increased, the levels of vitamin A and 25-(OH)D3 decreased. Meanwhile, we noticed a rise in inflammatory markers such as TG2, IL-4, and IL-13. Interestingly, we found a strong negative correlation between the levels of vitamin A and 25-(OH)D3 and the eczema severity scores, indicating that lower vitamin D levels were associated with more severe eczema symptoms.
After three months of treatment, children across all severity groups showed significant improvement in their vitamin A and D3 levels, along with changes in the inflammatory markers. Notably, 25-(OH)D3 demonstrated the best accuracy in diagnosing the severity of eczema compared to the other markers examined. This suggests that monitoring vitamin D3 could be quite valuable for assessing and managing eczema in children.
Overall, our study indicates that vitamin D3 plays a significant role in the severity of eczema symptoms, reinforcing the importance of maintaining healthy vitamin D levels for children suffering from this condition.
Read More
We investigated the impact of vitamin D3 supplementation on eczema severity in children. Over six weeks, a group of 22 children with moderate to severe atopic dermatitis took oral vitamin D3 weekly. We measured changes in their skin's expression of important proteins and how their eczema was doing overall.
The results were quite promising. After the treatment, not only did the children's vitamin D levels increase, but there was also a noticeable decrease in eczema severity as measured by the SCORAD index. Our findings revealed that both the vitamin D receptor and a skin defense protein called Cathelicidin saw significant increases—especially in areas affected by eczema. However, we found that levels of Thymic Stromal Lymphopoietin (another important skin factor) did not change after the treatment.
Overall, this study suggests that oral vitamin D3 can play a beneficial role in managing eczema in children, helping improve their skin health alongside enhancing important skin functions. This gives us new insights into how vitamin D3 might serve as a supportive treatment option.
Read More
Vitamin D3 reduces eczema riskMaternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
High relevance due to direct investigation
We investigated how maternal supplementation with vitamin D3 during pregnancy influences the risk of developing atopic eczema in children. Our research was part of the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS), a well-designed, double-blind, randomized placebo-controlled trial. Pregnant women in the study were assigned to take either 1000 IU of cholecalciferol (vitamin D3) or a placebo from around 14 weeks of gestation until delivery.
We tracked the prevalence of atopic eczema in their children at ages 12, 24, and 48 months, using recognized criteria for diagnosis. Our findings suggest that maternal cholecalciferol supplementation plays a beneficial role, as we noted a potential protective effect against the development of infantile atopic eczema. This effect might be due to increased levels of vitamin D3 in breast milk, which may help bolster the child’s immune system.
These results add valuable information to the conversation about how prenatal interventions can influence childhood health, particularly in relation to skin conditions like eczema.
Read More
Vitamin D boosts levels, not symptomsSerum 25-hydroxyvitamin D levels in patients with atopic eczema and the influence of narrowband ultraviolet B phototherapy.
Investigated vitamin D's effects
We examined how vitamin D3 levels affect atopic dermatitis, commonly known as eczema, particularly in patients undergoing narrowband ultraviolet B (nbUVB) therapy. This study involved 38 patients divided by gender and severity of their dermatitis, and tracked changes in both their vitamin D levels and their eczema severity before and after treatment.
Following the nbUVB therapy, we noted a remarkable increase in the median serum vitamin D levels—from 45 nmol/l before treatment to 169 nmol/l after treatment. Alongside this boost in vitamin D levels, we also observed a noteworthy reduction in eczema severity, with the average score dropping significantly.
However, our findings did not show a clear connection between the increase in vitamin D levels and the improvement in eczema severity. This suggests that while patients with eczema may benefit from increased vitamin D due to treatments like nbUVB, the direct relationship between vitamin D levels and eczema severity isn't confirmed by our study.
Overall, while patients with atopic dermatitis may be at risk of vitamin D deficiency, our results imply that simply increasing vitamin D levels might not guarantee improvements in eczema severity.
Read More
Vitamin D's role in eczema severityChanges and clinical significance of serum vitamin A, 25-(OH)D3, TG2, IL-4 and IL-13 levels in children with eczema.
High relevance; partial vitamin D focus
We investigated the levels of vitamin D and other related factors in children suffering from eczema to better understand their relationship with the severity of this condition. Our analysis included 159 children, categorized by the severity of their eczema symptoms into mild, moderate, and severe groups.
Over the course of the study, we observed that as eczema severity increased, serum levels of vitamin A and 25-(OH)D3 (a form of vitamin D) tended to decrease. Conversely, levels of tissue transglutaminase (TG2), interleukin-4 (IL-4), and interleukin-13 (IL-13), which are markers of inflammation, increased. Significant correlations emerged showing that lower levels of vitamin A and 25-(OH)D3 were linked to higher SCORAD scores (a measure of eczema severity), while increases in TG2, IL-4, and IL-13 levels paralleled worsening symptoms.
Importantly, vitamin D levels had the highest accuracy for assessing eczema severity compared to the other markers studied. After treatment over three months, we noted improvements in the levels of all measured indicators, suggesting that addressing these serum factors could have a positive impact on managing eczema symptoms.
Our findings indicate that monitoring vitamin D levels, along with other serum indicators, might offer valuable insights for clinicians in evaluating and treating eczema in children.
Read More